Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome

References

• Durani U, Shah ND, Go RS. In-hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample. Oncologist. 2017;22(12):1506–1509.
   PubMed Web of Science ®Google Scholar
• Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8(2):e55870–10.
   PubMed Web of Science ®Google Scholar
• Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma. 2008;8(1):44–51.
   PubMedGoogle Scholar
• Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77–83.
   PubMed Web of Science ®Google Scholar
• Garimella PS, Balakrishnan P, Ammakkanavar NR, et al. Impact of dialysis requirement on outcomes in tumor lysis syndrome. Nephrology. 2017;22(1):85–88.
   PubMed Web of Science ®Google Scholar
• Personett HA, Barreto EF, McCullough KB, et al. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leuk Lymphoma. 2019;0:1–7.
   Google Scholar
• Darmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162(4):489–497.
   PubMed Web of Science ®Google Scholar
• Shimada M, Johnson RJ, May WS, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24(10):2960–2964.
   PubMed Web of Science ®Google Scholar
• Sellmayr M, Hernandez Petzsche MR, Ma Q, et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol. 2020;31(12):2773–2792.
   PubMed Web of Science ®Google Scholar
• Ahsan Ejaz A, Pourafshar N, Mohandas R, et al. Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS One. 2015;10:5–15.
   Web of Science ®Google Scholar
• Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.
   PubMed Web of Science ®Google Scholar
• Koratala A, Singhania G, Alquadan KF, et al. Serum uric acid exhibits inverse relationship with estimated glomerular filtration rate. Nephron. 2016;134(4):231–237.
   PubMed Web of Science ®Google Scholar
• Russo E, Viazzi F, Pontremoli R, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. J Nephrol. 2021. [Internet]. https://doi.org/https://doi.org/10.1007/s40620-021-00985-4.
   Web of Science ®Google Scholar
• Cairo MS, Thompson S, Tangirala K, et al. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma, Myeloma Leuk. 2017;17(3):173–178.
   PubMed Web of Science ®Google Scholar
• Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–4213.
   PubMed Web of Science ®Google Scholar
• St. Sauver JL, Grossardt BR, Yawn BP, et al. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol. 2011;173(9):1059–1068.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Grossardt BR, Leibson CL, et al. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87(2):151–160.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
   PubMed Web of Science ®Google Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–257.
   PubMed Web of Science ®Google Scholar
• Wonnacott A, Meran S, Amphlett B, et al. Epidemiology and outcomes in community-acquired versus hospital-acquired aki. CJASN. 2014;9(6):1007–1014.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Altman A, Pui C-H, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–2778.
   PubMed Web of Science ®Google Scholar
• Kang D-H. Hyperuricemia and progression of chronic kidney disease: role of phenotype transition of renal tubular and endothelial cells. Contrib Nephrol. 2018;192:48–55.
   PubMed Web of Science ®Google Scholar
• Russo E, Drovandi S, Salvidio G, et al. Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy. Nutr Metab Cardiovasc Dis. 2020;30(12):2343–2350.
   PubMed Web of Science ®Google Scholar
• Odden MC, Amadu AR, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis. 2014;64(4):550–557. https://doi.org/http://dx.doi.org/10.1053/j.ajkd.2014.04.024.
   PubMed Web of Science ®Google Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–413.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia De Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543–549.
   PubMed Web of Science ®Google Scholar
• Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10):2998–3003.
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513.
   PubMed Web of Science ®Google Scholar
• Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–2503.
   PubMed Web of Science ®Google Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vacante M, Russo C, et al. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother. 2009;10(5):737–742.
   PubMed Web of Science ®Google Scholar
• Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020;33(4):715–724.
   PubMed Web of Science ®Google Scholar
• Villeneuve PM, Clark EG, Sikora L, et al. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit: a systematic review. Intensive Care Med. 2016;42(2):137–146.
   PubMed Web of Science ®Google Scholar
• Nisula S, Vaara ST, Kaukonen KM, et al. Six-month survival and quality of life of intensive care patients with acute kidney injury. Crit Care. 2013;17(5):R250.
   PubMed Web of Science ®Google Scholar
• Khurana A, Mwangi R, Nowakowski GS, et al. Impact of organ function–based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind? J Clin Oncol. 2021;39(15):1641–1649.
   PubMed Web of Science ®Google Scholar